210
Type I interferons (IFNs) are expressed by all nucleated cells in response to viral pathogens and modulate innate and adaptive immune responses by stimulating expression of subsets of interferon stimulated genes (ISGs). There are over 1000 ISGs, including more than 60 that are transcription factors...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Renn, Lynnsey A. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2013transfer abstract |
|---|
| Umfang: |
2 |
|---|
| Übergeordnetes Werk: |
Enthalten in: The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types - McLaughlin, Richard J. ELSEVIER, 2022, the official journal of the International Cytokine Society, Oxford [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:63 ; year:2013 ; number:3 ; pages:292-293 ; extent:2 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.cyto.2013.06.213 |
|---|
| Katalog-ID: |
ELV022163239 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV022163239 | ||
| 003 | DE-627 | ||
| 005 | 20230625134931.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cyto.2013.06.213 |2 doi | |
| 028 | 5 | 2 | |a GBVA2013017000028.pica |
| 035 | |a (DE-627)ELV022163239 | ||
| 035 | |a (ELSEVIER)S1043-4666(13)00487-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 | |
| 082 | 0 | 4 | |a 570 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.83 |2 bkl | ||
| 100 | 1 | |a Renn, Lynnsey A. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 210 |
| 264 | 1 | |c 2013transfer abstract | |
| 300 | |a 2 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Type I interferons (IFNs) are expressed by all nucleated cells in response to viral pathogens and modulate innate and adaptive immune responses by stimulating expression of subsets of interferon stimulated genes (ISGs). There are over 1000 ISGs, including more than 60 that are transcription factors (TFs). Type I IFNs share the same receptor complex and are comprised of multiple species, including IFN-beta, IFN-omega, and twelve subtypes of IFN-alpha. Both type I IFNs and the more recently described type III IFNs activate STAT1/STAT2 heterodimers and stimulate additional pathways that translate into antiviral and antiproliferative responses. It is not well understood how the timing and dose of each IFN contributes to these functional outcomes. We hypothesize that expression patterns of TFs will reveal unique functional responses to IFN subtypes, either alone or in combination. Therefore, we designed a quantitative-RT-PCR (qRT-PCR) array for detection of more than 50 TFs that are expressed in response to type I IFN (TF–ISGs). To test our hypothesis, we are characterizing expression of TF-ISGs by respiratory epithelial cells in response to increasing doses of types I and III IFN in a checkerboard pattern at discrete time points within 4h. In addition, we are correlating expression patterns of TF-ISGs and type I/III IFN (measured with our previously reported qRT-PCR based assay) in human peripheral blood mononuclear cells that have been stimulated with the TLR ligands polyinosinic:polycytidylic acid (poly I:C), lipopolysaccharides (LPS), imiquimod, and CpG oligonucleotides (receptors are RIG-I/TLR3, TLR4, TLR7 and TLR9, respectively). We predict that characterizing expression signatures of IFN subtypes and TF-ISGs will provide insight towards defining functional cellular responses to specific IFN subtypes. | ||
| 520 | |a Type I interferons (IFNs) are expressed by all nucleated cells in response to viral pathogens and modulate innate and adaptive immune responses by stimulating expression of subsets of interferon stimulated genes (ISGs). There are over 1000 ISGs, including more than 60 that are transcription factors (TFs). Type I IFNs share the same receptor complex and are comprised of multiple species, including IFN-beta, IFN-omega, and twelve subtypes of IFN-alpha. Both type I IFNs and the more recently described type III IFNs activate STAT1/STAT2 heterodimers and stimulate additional pathways that translate into antiviral and antiproliferative responses. It is not well understood how the timing and dose of each IFN contributes to these functional outcomes. We hypothesize that expression patterns of TFs will reveal unique functional responses to IFN subtypes, either alone or in combination. Therefore, we designed a quantitative-RT-PCR (qRT-PCR) array for detection of more than 50 TFs that are expressed in response to type I IFN (TF–ISGs). To test our hypothesis, we are characterizing expression of TF-ISGs by respiratory epithelial cells in response to increasing doses of types I and III IFN in a checkerboard pattern at discrete time points within 4h. In addition, we are correlating expression patterns of TF-ISGs and type I/III IFN (measured with our previously reported qRT-PCR based assay) in human peripheral blood mononuclear cells that have been stimulated with the TLR ligands polyinosinic:polycytidylic acid (poly I:C), lipopolysaccharides (LPS), imiquimod, and CpG oligonucleotides (receptors are RIG-I/TLR3, TLR4, TLR7 and TLR9, respectively). We predict that characterizing expression signatures of IFN subtypes and TF-ISGs will provide insight towards defining functional cellular responses to specific IFN subtypes. | ||
| 700 | 1 | |a Theisen, Terence C. |4 oth | |
| 700 | 1 | |a Hillyer, Philippa |4 oth | |
| 700 | 1 | |a Rabin, Ronald L. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a McLaughlin, Richard J. ELSEVIER |t The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types |d 2022 |d the official journal of the International Cytokine Society |g Oxford [u.a.] |w (DE-627)ELV008219540 |
| 773 | 1 | 8 | |g volume:63 |g year:2013 |g number:3 |g pages:292-293 |g extent:2 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.cyto.2013.06.213 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.83 |j Rheumatologie |j Orthopädie |q VZ |
| 951 | |a AR | ||
| 952 | |d 63 |j 2013 |e 3 |h 292-293 |g 2 | ||
| 953 | |2 045F |a 570 | ||
| author_variant |
l a r la lar |
|---|---|
| matchkey_str |
ELV022163239 |
| hierarchy_sort_str |
2013transfer abstract |
| bklnumber |
44.83 |
| publishDate |
2013 |
| allfields |
10.1016/j.cyto.2013.06.213 doi GBVA2013017000028.pica (DE-627)ELV022163239 (ELSEVIER)S1043-4666(13)00487-0 DE-627 ger DE-627 rakwb eng 570 570 DE-600 610 VZ 44.83 bkl Renn, Lynnsey A. verfasserin aut 210 2013transfer abstract 2 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Type I interferons (IFNs) are expressed by all nucleated cells in response to viral pathogens and modulate innate and adaptive immune responses by stimulating expression of subsets of interferon stimulated genes (ISGs). There are over 1000 ISGs, including more than 60 that are transcription factors (TFs). Type I IFNs share the same receptor complex and are comprised of multiple species, including IFN-beta, IFN-omega, and twelve subtypes of IFN-alpha. Both type I IFNs and the more recently described type III IFNs activate STAT1/STAT2 heterodimers and stimulate additional pathways that translate into antiviral and antiproliferative responses. It is not well understood how the timing and dose of each IFN contributes to these functional outcomes. We hypothesize that expression patterns of TFs will reveal unique functional responses to IFN subtypes, either alone or in combination. Therefore, we designed a quantitative-RT-PCR (qRT-PCR) array for detection of more than 50 TFs that are expressed in response to type I IFN (TF–ISGs). To test our hypothesis, we are characterizing expression of TF-ISGs by respiratory epithelial cells in response to increasing doses of types I and III IFN in a checkerboard pattern at discrete time points within 4h. In addition, we are correlating expression patterns of TF-ISGs and type I/III IFN (measured with our previously reported qRT-PCR based assay) in human peripheral blood mononuclear cells that have been stimulated with the TLR ligands polyinosinic:polycytidylic acid (poly I:C), lipopolysaccharides (LPS), imiquimod, and CpG oligonucleotides (receptors are RIG-I/TLR3, TLR4, TLR7 and TLR9, respectively). We predict that characterizing expression signatures of IFN subtypes and TF-ISGs will provide insight towards defining functional cellular responses to specific IFN subtypes. Type I interferons (IFNs) are expressed by all nucleated cells in response to viral pathogens and modulate innate and adaptive immune responses by stimulating expression of subsets of interferon stimulated genes (ISGs). There are over 1000 ISGs, including more than 60 that are transcription factors (TFs). Type I IFNs share the same receptor complex and are comprised of multiple species, including IFN-beta, IFN-omega, and twelve subtypes of IFN-alpha. Both type I IFNs and the more recently described type III IFNs activate STAT1/STAT2 heterodimers and stimulate additional pathways that translate into antiviral and antiproliferative responses. It is not well understood how the timing and dose of each IFN contributes to these functional outcomes. We hypothesize that expression patterns of TFs will reveal unique functional responses to IFN subtypes, either alone or in combination. Therefore, we designed a quantitative-RT-PCR (qRT-PCR) array for detection of more than 50 TFs that are expressed in response to type I IFN (TF–ISGs). To test our hypothesis, we are characterizing expression of TF-ISGs by respiratory epithelial cells in response to increasing doses of types I and III IFN in a checkerboard pattern at discrete time points within 4h. In addition, we are correlating expression patterns of TF-ISGs and type I/III IFN (measured with our previously reported qRT-PCR based assay) in human peripheral blood mononuclear cells that have been stimulated with the TLR ligands polyinosinic:polycytidylic acid (poly I:C), lipopolysaccharides (LPS), imiquimod, and CpG oligonucleotides (receptors are RIG-I/TLR3, TLR4, TLR7 and TLR9, respectively). We predict that characterizing expression signatures of IFN subtypes and TF-ISGs will provide insight towards defining functional cellular responses to specific IFN subtypes. Theisen, Terence C. oth Hillyer, Philippa oth Rabin, Ronald L. oth Enthalten in Elsevier McLaughlin, Richard J. ELSEVIER The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types 2022 the official journal of the International Cytokine Society Oxford [u.a.] (DE-627)ELV008219540 volume:63 year:2013 number:3 pages:292-293 extent:2 https://doi.org/10.1016/j.cyto.2013.06.213 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.83 Rheumatologie Orthopädie VZ AR 63 2013 3 292-293 2 045F 570 |
| spelling |
10.1016/j.cyto.2013.06.213 doi GBVA2013017000028.pica (DE-627)ELV022163239 (ELSEVIER)S1043-4666(13)00487-0 DE-627 ger DE-627 rakwb eng 570 570 DE-600 610 VZ 44.83 bkl Renn, Lynnsey A. verfasserin aut 210 2013transfer abstract 2 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Type I interferons (IFNs) are expressed by all nucleated cells in response to viral pathogens and modulate innate and adaptive immune responses by stimulating expression of subsets of interferon stimulated genes (ISGs). There are over 1000 ISGs, including more than 60 that are transcription factors (TFs). Type I IFNs share the same receptor complex and are comprised of multiple species, including IFN-beta, IFN-omega, and twelve subtypes of IFN-alpha. Both type I IFNs and the more recently described type III IFNs activate STAT1/STAT2 heterodimers and stimulate additional pathways that translate into antiviral and antiproliferative responses. It is not well understood how the timing and dose of each IFN contributes to these functional outcomes. We hypothesize that expression patterns of TFs will reveal unique functional responses to IFN subtypes, either alone or in combination. Therefore, we designed a quantitative-RT-PCR (qRT-PCR) array for detection of more than 50 TFs that are expressed in response to type I IFN (TF–ISGs). To test our hypothesis, we are characterizing expression of TF-ISGs by respiratory epithelial cells in response to increasing doses of types I and III IFN in a checkerboard pattern at discrete time points within 4h. In addition, we are correlating expression patterns of TF-ISGs and type I/III IFN (measured with our previously reported qRT-PCR based assay) in human peripheral blood mononuclear cells that have been stimulated with the TLR ligands polyinosinic:polycytidylic acid (poly I:C), lipopolysaccharides (LPS), imiquimod, and CpG oligonucleotides (receptors are RIG-I/TLR3, TLR4, TLR7 and TLR9, respectively). We predict that characterizing expression signatures of IFN subtypes and TF-ISGs will provide insight towards defining functional cellular responses to specific IFN subtypes. Type I interferons (IFNs) are expressed by all nucleated cells in response to viral pathogens and modulate innate and adaptive immune responses by stimulating expression of subsets of interferon stimulated genes (ISGs). There are over 1000 ISGs, including more than 60 that are transcription factors (TFs). Type I IFNs share the same receptor complex and are comprised of multiple species, including IFN-beta, IFN-omega, and twelve subtypes of IFN-alpha. Both type I IFNs and the more recently described type III IFNs activate STAT1/STAT2 heterodimers and stimulate additional pathways that translate into antiviral and antiproliferative responses. It is not well understood how the timing and dose of each IFN contributes to these functional outcomes. We hypothesize that expression patterns of TFs will reveal unique functional responses to IFN subtypes, either alone or in combination. Therefore, we designed a quantitative-RT-PCR (qRT-PCR) array for detection of more than 50 TFs that are expressed in response to type I IFN (TF–ISGs). To test our hypothesis, we are characterizing expression of TF-ISGs by respiratory epithelial cells in response to increasing doses of types I and III IFN in a checkerboard pattern at discrete time points within 4h. In addition, we are correlating expression patterns of TF-ISGs and type I/III IFN (measured with our previously reported qRT-PCR based assay) in human peripheral blood mononuclear cells that have been stimulated with the TLR ligands polyinosinic:polycytidylic acid (poly I:C), lipopolysaccharides (LPS), imiquimod, and CpG oligonucleotides (receptors are RIG-I/TLR3, TLR4, TLR7 and TLR9, respectively). We predict that characterizing expression signatures of IFN subtypes and TF-ISGs will provide insight towards defining functional cellular responses to specific IFN subtypes. Theisen, Terence C. oth Hillyer, Philippa oth Rabin, Ronald L. oth Enthalten in Elsevier McLaughlin, Richard J. ELSEVIER The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types 2022 the official journal of the International Cytokine Society Oxford [u.a.] (DE-627)ELV008219540 volume:63 year:2013 number:3 pages:292-293 extent:2 https://doi.org/10.1016/j.cyto.2013.06.213 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.83 Rheumatologie Orthopädie VZ AR 63 2013 3 292-293 2 045F 570 |
| allfields_unstemmed |
10.1016/j.cyto.2013.06.213 doi GBVA2013017000028.pica (DE-627)ELV022163239 (ELSEVIER)S1043-4666(13)00487-0 DE-627 ger DE-627 rakwb eng 570 570 DE-600 610 VZ 44.83 bkl Renn, Lynnsey A. verfasserin aut 210 2013transfer abstract 2 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Type I interferons (IFNs) are expressed by all nucleated cells in response to viral pathogens and modulate innate and adaptive immune responses by stimulating expression of subsets of interferon stimulated genes (ISGs). There are over 1000 ISGs, including more than 60 that are transcription factors (TFs). Type I IFNs share the same receptor complex and are comprised of multiple species, including IFN-beta, IFN-omega, and twelve subtypes of IFN-alpha. Both type I IFNs and the more recently described type III IFNs activate STAT1/STAT2 heterodimers and stimulate additional pathways that translate into antiviral and antiproliferative responses. It is not well understood how the timing and dose of each IFN contributes to these functional outcomes. We hypothesize that expression patterns of TFs will reveal unique functional responses to IFN subtypes, either alone or in combination. Therefore, we designed a quantitative-RT-PCR (qRT-PCR) array for detection of more than 50 TFs that are expressed in response to type I IFN (TF–ISGs). To test our hypothesis, we are characterizing expression of TF-ISGs by respiratory epithelial cells in response to increasing doses of types I and III IFN in a checkerboard pattern at discrete time points within 4h. In addition, we are correlating expression patterns of TF-ISGs and type I/III IFN (measured with our previously reported qRT-PCR based assay) in human peripheral blood mononuclear cells that have been stimulated with the TLR ligands polyinosinic:polycytidylic acid (poly I:C), lipopolysaccharides (LPS), imiquimod, and CpG oligonucleotides (receptors are RIG-I/TLR3, TLR4, TLR7 and TLR9, respectively). We predict that characterizing expression signatures of IFN subtypes and TF-ISGs will provide insight towards defining functional cellular responses to specific IFN subtypes. Type I interferons (IFNs) are expressed by all nucleated cells in response to viral pathogens and modulate innate and adaptive immune responses by stimulating expression of subsets of interferon stimulated genes (ISGs). There are over 1000 ISGs, including more than 60 that are transcription factors (TFs). Type I IFNs share the same receptor complex and are comprised of multiple species, including IFN-beta, IFN-omega, and twelve subtypes of IFN-alpha. Both type I IFNs and the more recently described type III IFNs activate STAT1/STAT2 heterodimers and stimulate additional pathways that translate into antiviral and antiproliferative responses. It is not well understood how the timing and dose of each IFN contributes to these functional outcomes. We hypothesize that expression patterns of TFs will reveal unique functional responses to IFN subtypes, either alone or in combination. Therefore, we designed a quantitative-RT-PCR (qRT-PCR) array for detection of more than 50 TFs that are expressed in response to type I IFN (TF–ISGs). To test our hypothesis, we are characterizing expression of TF-ISGs by respiratory epithelial cells in response to increasing doses of types I and III IFN in a checkerboard pattern at discrete time points within 4h. In addition, we are correlating expression patterns of TF-ISGs and type I/III IFN (measured with our previously reported qRT-PCR based assay) in human peripheral blood mononuclear cells that have been stimulated with the TLR ligands polyinosinic:polycytidylic acid (poly I:C), lipopolysaccharides (LPS), imiquimod, and CpG oligonucleotides (receptors are RIG-I/TLR3, TLR4, TLR7 and TLR9, respectively). We predict that characterizing expression signatures of IFN subtypes and TF-ISGs will provide insight towards defining functional cellular responses to specific IFN subtypes. Theisen, Terence C. oth Hillyer, Philippa oth Rabin, Ronald L. oth Enthalten in Elsevier McLaughlin, Richard J. ELSEVIER The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types 2022 the official journal of the International Cytokine Society Oxford [u.a.] (DE-627)ELV008219540 volume:63 year:2013 number:3 pages:292-293 extent:2 https://doi.org/10.1016/j.cyto.2013.06.213 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.83 Rheumatologie Orthopädie VZ AR 63 2013 3 292-293 2 045F 570 |
| allfieldsGer |
10.1016/j.cyto.2013.06.213 doi GBVA2013017000028.pica (DE-627)ELV022163239 (ELSEVIER)S1043-4666(13)00487-0 DE-627 ger DE-627 rakwb eng 570 570 DE-600 610 VZ 44.83 bkl Renn, Lynnsey A. verfasserin aut 210 2013transfer abstract 2 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Type I interferons (IFNs) are expressed by all nucleated cells in response to viral pathogens and modulate innate and adaptive immune responses by stimulating expression of subsets of interferon stimulated genes (ISGs). There are over 1000 ISGs, including more than 60 that are transcription factors (TFs). Type I IFNs share the same receptor complex and are comprised of multiple species, including IFN-beta, IFN-omega, and twelve subtypes of IFN-alpha. Both type I IFNs and the more recently described type III IFNs activate STAT1/STAT2 heterodimers and stimulate additional pathways that translate into antiviral and antiproliferative responses. It is not well understood how the timing and dose of each IFN contributes to these functional outcomes. We hypothesize that expression patterns of TFs will reveal unique functional responses to IFN subtypes, either alone or in combination. Therefore, we designed a quantitative-RT-PCR (qRT-PCR) array for detection of more than 50 TFs that are expressed in response to type I IFN (TF–ISGs). To test our hypothesis, we are characterizing expression of TF-ISGs by respiratory epithelial cells in response to increasing doses of types I and III IFN in a checkerboard pattern at discrete time points within 4h. In addition, we are correlating expression patterns of TF-ISGs and type I/III IFN (measured with our previously reported qRT-PCR based assay) in human peripheral blood mononuclear cells that have been stimulated with the TLR ligands polyinosinic:polycytidylic acid (poly I:C), lipopolysaccharides (LPS), imiquimod, and CpG oligonucleotides (receptors are RIG-I/TLR3, TLR4, TLR7 and TLR9, respectively). We predict that characterizing expression signatures of IFN subtypes and TF-ISGs will provide insight towards defining functional cellular responses to specific IFN subtypes. Type I interferons (IFNs) are expressed by all nucleated cells in response to viral pathogens and modulate innate and adaptive immune responses by stimulating expression of subsets of interferon stimulated genes (ISGs). There are over 1000 ISGs, including more than 60 that are transcription factors (TFs). Type I IFNs share the same receptor complex and are comprised of multiple species, including IFN-beta, IFN-omega, and twelve subtypes of IFN-alpha. Both type I IFNs and the more recently described type III IFNs activate STAT1/STAT2 heterodimers and stimulate additional pathways that translate into antiviral and antiproliferative responses. It is not well understood how the timing and dose of each IFN contributes to these functional outcomes. We hypothesize that expression patterns of TFs will reveal unique functional responses to IFN subtypes, either alone or in combination. Therefore, we designed a quantitative-RT-PCR (qRT-PCR) array for detection of more than 50 TFs that are expressed in response to type I IFN (TF–ISGs). To test our hypothesis, we are characterizing expression of TF-ISGs by respiratory epithelial cells in response to increasing doses of types I and III IFN in a checkerboard pattern at discrete time points within 4h. In addition, we are correlating expression patterns of TF-ISGs and type I/III IFN (measured with our previously reported qRT-PCR based assay) in human peripheral blood mononuclear cells that have been stimulated with the TLR ligands polyinosinic:polycytidylic acid (poly I:C), lipopolysaccharides (LPS), imiquimod, and CpG oligonucleotides (receptors are RIG-I/TLR3, TLR4, TLR7 and TLR9, respectively). We predict that characterizing expression signatures of IFN subtypes and TF-ISGs will provide insight towards defining functional cellular responses to specific IFN subtypes. Theisen, Terence C. oth Hillyer, Philippa oth Rabin, Ronald L. oth Enthalten in Elsevier McLaughlin, Richard J. ELSEVIER The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types 2022 the official journal of the International Cytokine Society Oxford [u.a.] (DE-627)ELV008219540 volume:63 year:2013 number:3 pages:292-293 extent:2 https://doi.org/10.1016/j.cyto.2013.06.213 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.83 Rheumatologie Orthopädie VZ AR 63 2013 3 292-293 2 045F 570 |
| allfieldsSound |
10.1016/j.cyto.2013.06.213 doi GBVA2013017000028.pica (DE-627)ELV022163239 (ELSEVIER)S1043-4666(13)00487-0 DE-627 ger DE-627 rakwb eng 570 570 DE-600 610 VZ 44.83 bkl Renn, Lynnsey A. verfasserin aut 210 2013transfer abstract 2 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Type I interferons (IFNs) are expressed by all nucleated cells in response to viral pathogens and modulate innate and adaptive immune responses by stimulating expression of subsets of interferon stimulated genes (ISGs). There are over 1000 ISGs, including more than 60 that are transcription factors (TFs). Type I IFNs share the same receptor complex and are comprised of multiple species, including IFN-beta, IFN-omega, and twelve subtypes of IFN-alpha. Both type I IFNs and the more recently described type III IFNs activate STAT1/STAT2 heterodimers and stimulate additional pathways that translate into antiviral and antiproliferative responses. It is not well understood how the timing and dose of each IFN contributes to these functional outcomes. We hypothesize that expression patterns of TFs will reveal unique functional responses to IFN subtypes, either alone or in combination. Therefore, we designed a quantitative-RT-PCR (qRT-PCR) array for detection of more than 50 TFs that are expressed in response to type I IFN (TF–ISGs). To test our hypothesis, we are characterizing expression of TF-ISGs by respiratory epithelial cells in response to increasing doses of types I and III IFN in a checkerboard pattern at discrete time points within 4h. In addition, we are correlating expression patterns of TF-ISGs and type I/III IFN (measured with our previously reported qRT-PCR based assay) in human peripheral blood mononuclear cells that have been stimulated with the TLR ligands polyinosinic:polycytidylic acid (poly I:C), lipopolysaccharides (LPS), imiquimod, and CpG oligonucleotides (receptors are RIG-I/TLR3, TLR4, TLR7 and TLR9, respectively). We predict that characterizing expression signatures of IFN subtypes and TF-ISGs will provide insight towards defining functional cellular responses to specific IFN subtypes. Type I interferons (IFNs) are expressed by all nucleated cells in response to viral pathogens and modulate innate and adaptive immune responses by stimulating expression of subsets of interferon stimulated genes (ISGs). There are over 1000 ISGs, including more than 60 that are transcription factors (TFs). Type I IFNs share the same receptor complex and are comprised of multiple species, including IFN-beta, IFN-omega, and twelve subtypes of IFN-alpha. Both type I IFNs and the more recently described type III IFNs activate STAT1/STAT2 heterodimers and stimulate additional pathways that translate into antiviral and antiproliferative responses. It is not well understood how the timing and dose of each IFN contributes to these functional outcomes. We hypothesize that expression patterns of TFs will reveal unique functional responses to IFN subtypes, either alone or in combination. Therefore, we designed a quantitative-RT-PCR (qRT-PCR) array for detection of more than 50 TFs that are expressed in response to type I IFN (TF–ISGs). To test our hypothesis, we are characterizing expression of TF-ISGs by respiratory epithelial cells in response to increasing doses of types I and III IFN in a checkerboard pattern at discrete time points within 4h. In addition, we are correlating expression patterns of TF-ISGs and type I/III IFN (measured with our previously reported qRT-PCR based assay) in human peripheral blood mononuclear cells that have been stimulated with the TLR ligands polyinosinic:polycytidylic acid (poly I:C), lipopolysaccharides (LPS), imiquimod, and CpG oligonucleotides (receptors are RIG-I/TLR3, TLR4, TLR7 and TLR9, respectively). We predict that characterizing expression signatures of IFN subtypes and TF-ISGs will provide insight towards defining functional cellular responses to specific IFN subtypes. Theisen, Terence C. oth Hillyer, Philippa oth Rabin, Ronald L. oth Enthalten in Elsevier McLaughlin, Richard J. ELSEVIER The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types 2022 the official journal of the International Cytokine Society Oxford [u.a.] (DE-627)ELV008219540 volume:63 year:2013 number:3 pages:292-293 extent:2 https://doi.org/10.1016/j.cyto.2013.06.213 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.83 Rheumatologie Orthopädie VZ AR 63 2013 3 292-293 2 045F 570 |
| language |
English |
| source |
Enthalten in The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types Oxford [u.a.] volume:63 year:2013 number:3 pages:292-293 extent:2 |
| sourceStr |
Enthalten in The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types Oxford [u.a.] volume:63 year:2013 number:3 pages:292-293 extent:2 |
| format_phy_str_mv |
Article |
| bklname |
Rheumatologie Orthopädie |
| institution |
findex.gbv.de |
| dewey-raw |
570 |
| isfreeaccess_bool |
false |
| container_title |
The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types |
| authorswithroles_txt_mv |
Renn, Lynnsey A. @@aut@@ Theisen, Terence C. @@oth@@ Hillyer, Philippa @@oth@@ Rabin, Ronald L. @@oth@@ |
| publishDateDaySort_date |
2013-01-01T00:00:00Z |
| hierarchy_top_id |
ELV008219540 |
| dewey-sort |
3570 |
| id |
ELV022163239 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV022163239</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625134931.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.cyto.2013.06.213</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013017000028.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV022163239</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1043-4666(13)00487-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">570</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.83</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Renn, Lynnsey A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">210</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">2</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Type I interferons (IFNs) are expressed by all nucleated cells in response to viral pathogens and modulate innate and adaptive immune responses by stimulating expression of subsets of interferon stimulated genes (ISGs). There are over 1000 ISGs, including more than 60 that are transcription factors (TFs). Type I IFNs share the same receptor complex and are comprised of multiple species, including IFN-beta, IFN-omega, and twelve subtypes of IFN-alpha. Both type I IFNs and the more recently described type III IFNs activate STAT1/STAT2 heterodimers and stimulate additional pathways that translate into antiviral and antiproliferative responses. It is not well understood how the timing and dose of each IFN contributes to these functional outcomes. We hypothesize that expression patterns of TFs will reveal unique functional responses to IFN subtypes, either alone or in combination. Therefore, we designed a quantitative-RT-PCR (qRT-PCR) array for detection of more than 50 TFs that are expressed in response to type I IFN (TF–ISGs). To test our hypothesis, we are characterizing expression of TF-ISGs by respiratory epithelial cells in response to increasing doses of types I and III IFN in a checkerboard pattern at discrete time points within 4h. In addition, we are correlating expression patterns of TF-ISGs and type I/III IFN (measured with our previously reported qRT-PCR based assay) in human peripheral blood mononuclear cells that have been stimulated with the TLR ligands polyinosinic:polycytidylic acid (poly I:C), lipopolysaccharides (LPS), imiquimod, and CpG oligonucleotides (receptors are RIG-I/TLR3, TLR4, TLR7 and TLR9, respectively). We predict that characterizing expression signatures of IFN subtypes and TF-ISGs will provide insight towards defining functional cellular responses to specific IFN subtypes.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Type I interferons (IFNs) are expressed by all nucleated cells in response to viral pathogens and modulate innate and adaptive immune responses by stimulating expression of subsets of interferon stimulated genes (ISGs). There are over 1000 ISGs, including more than 60 that are transcription factors (TFs). Type I IFNs share the same receptor complex and are comprised of multiple species, including IFN-beta, IFN-omega, and twelve subtypes of IFN-alpha. Both type I IFNs and the more recently described type III IFNs activate STAT1/STAT2 heterodimers and stimulate additional pathways that translate into antiviral and antiproliferative responses. It is not well understood how the timing and dose of each IFN contributes to these functional outcomes. We hypothesize that expression patterns of TFs will reveal unique functional responses to IFN subtypes, either alone or in combination. Therefore, we designed a quantitative-RT-PCR (qRT-PCR) array for detection of more than 50 TFs that are expressed in response to type I IFN (TF–ISGs). To test our hypothesis, we are characterizing expression of TF-ISGs by respiratory epithelial cells in response to increasing doses of types I and III IFN in a checkerboard pattern at discrete time points within 4h. In addition, we are correlating expression patterns of TF-ISGs and type I/III IFN (measured with our previously reported qRT-PCR based assay) in human peripheral blood mononuclear cells that have been stimulated with the TLR ligands polyinosinic:polycytidylic acid (poly I:C), lipopolysaccharides (LPS), imiquimod, and CpG oligonucleotides (receptors are RIG-I/TLR3, TLR4, TLR7 and TLR9, respectively). We predict that characterizing expression signatures of IFN subtypes and TF-ISGs will provide insight towards defining functional cellular responses to specific IFN subtypes.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Theisen, Terence C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hillyer, Philippa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rabin, Ronald L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">McLaughlin, Richard J. ELSEVIER</subfield><subfield code="t">The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types</subfield><subfield code="d">2022</subfield><subfield code="d">the official journal of the International Cytokine Society</subfield><subfield code="g">Oxford [u.a.]</subfield><subfield code="w">(DE-627)ELV008219540</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:63</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:292-293</subfield><subfield code="g">extent:2</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.cyto.2013.06.213</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.83</subfield><subfield code="j">Rheumatologie</subfield><subfield code="j">Orthopädie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">63</subfield><subfield code="j">2013</subfield><subfield code="e">3</subfield><subfield code="h">292-293</subfield><subfield code="g">2</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">570</subfield></datafield></record></collection>
|
| author |
Renn, Lynnsey A. |
| spellingShingle |
Renn, Lynnsey A. ddc 570 ddc 610 bkl 44.83 210 |
| authorStr |
Renn, Lynnsey A. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV008219540 |
| format |
electronic Article |
| dewey-ones |
570 - Life sciences; biology 610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
570 570 DE-600 610 VZ 44.83 bkl 210 |
| topic |
ddc 570 ddc 610 bkl 44.83 |
| topic_unstemmed |
ddc 570 ddc 610 bkl 44.83 |
| topic_browse |
ddc 570 ddc 610 bkl 44.83 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
t c t tc tct p h ph r l r rl rlr |
| hierarchy_parent_title |
The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types |
| hierarchy_parent_id |
ELV008219540 |
| dewey-tens |
570 - Life sciences; biology 610 - Medicine & health |
| hierarchy_top_title |
The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV008219540 |
| title |
210 |
| ctrlnum |
(DE-627)ELV022163239 (ELSEVIER)S1043-4666(13)00487-0 |
| title_full |
210 |
| author_sort |
Renn, Lynnsey A. |
| journal |
The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types |
| journalStr |
The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science 600 - Technology |
| recordtype |
marc |
| publishDateSort |
2013 |
| contenttype_str_mv |
zzz |
| container_start_page |
292 |
| author_browse |
Renn, Lynnsey A. |
| container_volume |
63 |
| physical |
2 |
| class |
570 570 DE-600 610 VZ 44.83 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Renn, Lynnsey A. |
| doi_str_mv |
10.1016/j.cyto.2013.06.213 |
| dewey-full |
570 610 |
| title_sort |
210 |
| title_auth |
210 |
| abstract |
Type I interferons (IFNs) are expressed by all nucleated cells in response to viral pathogens and modulate innate and adaptive immune responses by stimulating expression of subsets of interferon stimulated genes (ISGs). There are over 1000 ISGs, including more than 60 that are transcription factors (TFs). Type I IFNs share the same receptor complex and are comprised of multiple species, including IFN-beta, IFN-omega, and twelve subtypes of IFN-alpha. Both type I IFNs and the more recently described type III IFNs activate STAT1/STAT2 heterodimers and stimulate additional pathways that translate into antiviral and antiproliferative responses. It is not well understood how the timing and dose of each IFN contributes to these functional outcomes. We hypothesize that expression patterns of TFs will reveal unique functional responses to IFN subtypes, either alone or in combination. Therefore, we designed a quantitative-RT-PCR (qRT-PCR) array for detection of more than 50 TFs that are expressed in response to type I IFN (TF–ISGs). To test our hypothesis, we are characterizing expression of TF-ISGs by respiratory epithelial cells in response to increasing doses of types I and III IFN in a checkerboard pattern at discrete time points within 4h. In addition, we are correlating expression patterns of TF-ISGs and type I/III IFN (measured with our previously reported qRT-PCR based assay) in human peripheral blood mononuclear cells that have been stimulated with the TLR ligands polyinosinic:polycytidylic acid (poly I:C), lipopolysaccharides (LPS), imiquimod, and CpG oligonucleotides (receptors are RIG-I/TLR3, TLR4, TLR7 and TLR9, respectively). We predict that characterizing expression signatures of IFN subtypes and TF-ISGs will provide insight towards defining functional cellular responses to specific IFN subtypes. |
| abstractGer |
Type I interferons (IFNs) are expressed by all nucleated cells in response to viral pathogens and modulate innate and adaptive immune responses by stimulating expression of subsets of interferon stimulated genes (ISGs). There are over 1000 ISGs, including more than 60 that are transcription factors (TFs). Type I IFNs share the same receptor complex and are comprised of multiple species, including IFN-beta, IFN-omega, and twelve subtypes of IFN-alpha. Both type I IFNs and the more recently described type III IFNs activate STAT1/STAT2 heterodimers and stimulate additional pathways that translate into antiviral and antiproliferative responses. It is not well understood how the timing and dose of each IFN contributes to these functional outcomes. We hypothesize that expression patterns of TFs will reveal unique functional responses to IFN subtypes, either alone or in combination. Therefore, we designed a quantitative-RT-PCR (qRT-PCR) array for detection of more than 50 TFs that are expressed in response to type I IFN (TF–ISGs). To test our hypothesis, we are characterizing expression of TF-ISGs by respiratory epithelial cells in response to increasing doses of types I and III IFN in a checkerboard pattern at discrete time points within 4h. In addition, we are correlating expression patterns of TF-ISGs and type I/III IFN (measured with our previously reported qRT-PCR based assay) in human peripheral blood mononuclear cells that have been stimulated with the TLR ligands polyinosinic:polycytidylic acid (poly I:C), lipopolysaccharides (LPS), imiquimod, and CpG oligonucleotides (receptors are RIG-I/TLR3, TLR4, TLR7 and TLR9, respectively). We predict that characterizing expression signatures of IFN subtypes and TF-ISGs will provide insight towards defining functional cellular responses to specific IFN subtypes. |
| abstract_unstemmed |
Type I interferons (IFNs) are expressed by all nucleated cells in response to viral pathogens and modulate innate and adaptive immune responses by stimulating expression of subsets of interferon stimulated genes (ISGs). There are over 1000 ISGs, including more than 60 that are transcription factors (TFs). Type I IFNs share the same receptor complex and are comprised of multiple species, including IFN-beta, IFN-omega, and twelve subtypes of IFN-alpha. Both type I IFNs and the more recently described type III IFNs activate STAT1/STAT2 heterodimers and stimulate additional pathways that translate into antiviral and antiproliferative responses. It is not well understood how the timing and dose of each IFN contributes to these functional outcomes. We hypothesize that expression patterns of TFs will reveal unique functional responses to IFN subtypes, either alone or in combination. Therefore, we designed a quantitative-RT-PCR (qRT-PCR) array for detection of more than 50 TFs that are expressed in response to type I IFN (TF–ISGs). To test our hypothesis, we are characterizing expression of TF-ISGs by respiratory epithelial cells in response to increasing doses of types I and III IFN in a checkerboard pattern at discrete time points within 4h. In addition, we are correlating expression patterns of TF-ISGs and type I/III IFN (measured with our previously reported qRT-PCR based assay) in human peripheral blood mononuclear cells that have been stimulated with the TLR ligands polyinosinic:polycytidylic acid (poly I:C), lipopolysaccharides (LPS), imiquimod, and CpG oligonucleotides (receptors are RIG-I/TLR3, TLR4, TLR7 and TLR9, respectively). We predict that characterizing expression signatures of IFN subtypes and TF-ISGs will provide insight towards defining functional cellular responses to specific IFN subtypes. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
3 |
| title_short |
210 |
| url |
https://doi.org/10.1016/j.cyto.2013.06.213 |
| remote_bool |
true |
| author2 |
Theisen, Terence C. Hillyer, Philippa Rabin, Ronald L. |
| author2Str |
Theisen, Terence C. Hillyer, Philippa Rabin, Ronald L. |
| ppnlink |
ELV008219540 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/j.cyto.2013.06.213 |
| up_date |
2024-07-06T21:19:13.387Z |
| _version_ |
1803866082785624064 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV022163239</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625134931.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.cyto.2013.06.213</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013017000028.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV022163239</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1043-4666(13)00487-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">570</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.83</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Renn, Lynnsey A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">210</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">2</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Type I interferons (IFNs) are expressed by all nucleated cells in response to viral pathogens and modulate innate and adaptive immune responses by stimulating expression of subsets of interferon stimulated genes (ISGs). There are over 1000 ISGs, including more than 60 that are transcription factors (TFs). Type I IFNs share the same receptor complex and are comprised of multiple species, including IFN-beta, IFN-omega, and twelve subtypes of IFN-alpha. Both type I IFNs and the more recently described type III IFNs activate STAT1/STAT2 heterodimers and stimulate additional pathways that translate into antiviral and antiproliferative responses. It is not well understood how the timing and dose of each IFN contributes to these functional outcomes. We hypothesize that expression patterns of TFs will reveal unique functional responses to IFN subtypes, either alone or in combination. Therefore, we designed a quantitative-RT-PCR (qRT-PCR) array for detection of more than 50 TFs that are expressed in response to type I IFN (TF–ISGs). To test our hypothesis, we are characterizing expression of TF-ISGs by respiratory epithelial cells in response to increasing doses of types I and III IFN in a checkerboard pattern at discrete time points within 4h. In addition, we are correlating expression patterns of TF-ISGs and type I/III IFN (measured with our previously reported qRT-PCR based assay) in human peripheral blood mononuclear cells that have been stimulated with the TLR ligands polyinosinic:polycytidylic acid (poly I:C), lipopolysaccharides (LPS), imiquimod, and CpG oligonucleotides (receptors are RIG-I/TLR3, TLR4, TLR7 and TLR9, respectively). We predict that characterizing expression signatures of IFN subtypes and TF-ISGs will provide insight towards defining functional cellular responses to specific IFN subtypes.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Type I interferons (IFNs) are expressed by all nucleated cells in response to viral pathogens and modulate innate and adaptive immune responses by stimulating expression of subsets of interferon stimulated genes (ISGs). There are over 1000 ISGs, including more than 60 that are transcription factors (TFs). Type I IFNs share the same receptor complex and are comprised of multiple species, including IFN-beta, IFN-omega, and twelve subtypes of IFN-alpha. Both type I IFNs and the more recently described type III IFNs activate STAT1/STAT2 heterodimers and stimulate additional pathways that translate into antiviral and antiproliferative responses. It is not well understood how the timing and dose of each IFN contributes to these functional outcomes. We hypothesize that expression patterns of TFs will reveal unique functional responses to IFN subtypes, either alone or in combination. Therefore, we designed a quantitative-RT-PCR (qRT-PCR) array for detection of more than 50 TFs that are expressed in response to type I IFN (TF–ISGs). To test our hypothesis, we are characterizing expression of TF-ISGs by respiratory epithelial cells in response to increasing doses of types I and III IFN in a checkerboard pattern at discrete time points within 4h. In addition, we are correlating expression patterns of TF-ISGs and type I/III IFN (measured with our previously reported qRT-PCR based assay) in human peripheral blood mononuclear cells that have been stimulated with the TLR ligands polyinosinic:polycytidylic acid (poly I:C), lipopolysaccharides (LPS), imiquimod, and CpG oligonucleotides (receptors are RIG-I/TLR3, TLR4, TLR7 and TLR9, respectively). We predict that characterizing expression signatures of IFN subtypes and TF-ISGs will provide insight towards defining functional cellular responses to specific IFN subtypes.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Theisen, Terence C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hillyer, Philippa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rabin, Ronald L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">McLaughlin, Richard J. ELSEVIER</subfield><subfield code="t">The minimal clinically important differences of the Simple Shoulder Test are different for different arthroplasty types</subfield><subfield code="d">2022</subfield><subfield code="d">the official journal of the International Cytokine Society</subfield><subfield code="g">Oxford [u.a.]</subfield><subfield code="w">(DE-627)ELV008219540</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:63</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:292-293</subfield><subfield code="g">extent:2</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.cyto.2013.06.213</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.83</subfield><subfield code="j">Rheumatologie</subfield><subfield code="j">Orthopädie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">63</subfield><subfield code="j">2013</subfield><subfield code="e">3</subfield><subfield code="h">292-293</subfield><subfield code="g">2</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">570</subfield></datafield></record></collection>
|
| score |
7.4022284 |